[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623256":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":11,"studyPopulation":11,"armGroups":41,"interventions":54,"overallOfficials":11,"centralContacts":64,"locations":74,"responsibleParty":86,"collaborators":90,"id":92,"slug":11,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":11,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":11,"enrollmentInfo":100,"targetDuration":11,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":115,"whyStopped":11,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"German University in Cairo","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change of Global longitudinal strain value (GLS) of HF patients from the baseline",null,"6 weeks",[14,16,18,20,22,24,26,28],{"measure":15,"description":11,"timeFrame":12},"Change of heart failure symptoms as determined by NYHA classification from baseline",{"measure":17,"description":11,"timeFrame":12},"Change of the functional abilities (ECG) of the patients as determined by the exercise test from baseline",{"measure":19,"description":11,"timeFrame":12},"Changes in biomarkers of heart failure as determined by the difference in NT-proBNP levels from baseline",{"measure":21,"description":11,"timeFrame":12},"Change in quality of life between 2 groups as determined by Minnesota Living with Heart Failure questionnaire",{"measure":23,"description":11,"timeFrame":12},"Safety profile of the L-Arginine as determined by the change in the mean arterial pressure (MAP) between the 2 groups",{"measure":25,"description":11,"timeFrame":12},"Change in biomarkers of endothelial dysfunction as determined by the difference in levels of endothelin-1",{"measure":27,"description":11,"timeFrame":12},"Change in biomarkers of endothelial dysfunction as determined by the difference in levels of Asymmetric dimethylarginine (ADMA)",{"measure":29,"description":11,"timeFrame":12},"Safety profile of the L-Arginine as determined by the change in the heart rate (HR) between the 2 groups",{"allocation":31,"interventionModel":32,"interventionModelDescription":11,"primaryPurpose":33,"observationalModel":11,"timePerspective":11,"maskingInfo":34},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":35,"maskingDescription":11,"whoMasked":36},"QUADRUPLE",[37,38,39,40],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[42,48],{"label":43,"type":44,"description":45,"interventionNames":46},"L-Arginine Arm","ACTIVE_COMPARATOR","Patients in this arm will be administered 6 gm L-arginine per day",[47],"Drug: L-Arginine Powder",{"label":49,"type":50,"description":51,"interventionNames":52},"Placebo Arm","PLACEBO_COMPARATOR","Patients in this arm will take 6 gm placebo per day",[53],"Drug: Placebo",[55,60],{"type":56,"name":57,"description":58,"armGroupLabels":59,"otherNames":11},"DRUG","L-Arginine Powder","L-arginine 3 gm sachets are used twice daily",[43],{"type":56,"name":61,"description":62,"armGroupLabels":63,"otherNames":11},"Placebo","2 sachets of placebo are administered per day",[49],[65,70],{"name":66,"role":67,"phone":68,"phoneExt":11,"email":69},"Sara Araby, Msc","CONTACT","+201008662223","sara.araby96@gmail.com",{"name":71,"role":67,"phone":72,"phoneExt":11,"email":73},"Mohamed Solayman, PhD","+201005882550","mohamed.solayman@guc.edu.eg",[75],{"facility":76,"status":11,"city":77,"state":11,"zip":11,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":11},"Ain Shams University","Cairo","Egypt","EG",{"type":81,"coordinates":82},"Point",[83,84],31.24967,30.06263,{"lat":84,"lon":83},{"type":87,"investigatorFullName":88,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Sara Araby","Msc.",[91],{"name":76,"class":6},"100623256",false,"NCT07394270","Effect of Add-on L-Arginine Therapy on Heart Failure Patients","Effect of Add-on L-Arginine Therapy on Clinical Outcome of Heart Failure Patients: A Randomized- Controlled Trial","Inclusion Criteria:\n\n* Patients with EF \\\u003C40%\n* eGFR \\>30 mL\u002Fmin\u002F1.73 m2\n* Stable patients\n* Capable and willing to provide written consent\n\nExclusion Criteria:\n\n* Patients with implantable cardioverter-defibrillator\n* Pregnant or lactating fmeales\n* Patients with a history of sensitivity to L-Arginine or any of the excipients\n* Acute heart failure patients\n* Patients use L-arginine supplementation.\n* Patients with active herpes disease","ALL","19 Years",{"count":101,"type":102},200,"ESTIMATED","INTERVENTIONAL",[105],"PHASE2","Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \\\u003C40%",[108],"Heart Failure",[110,111,112,113,114],"Heart failure","Drug repurposing","L-Arginine","Add-on therapy","HFrEF","NOT_YET_RECRUITING","2026-02-01",{"date":118,"type":119},"2026-02-06","ACTUAL",{"date":121,"type":102},"2026-02",{"date":123,"type":102},"2027-07",{"name":5,"class":6},1]